Citations

Showing 10 of 108081 citations.

Hypermethylation of Synphilin-1, Alpha-Synuclein-Interacting Protein (SNCAIP) Gene in the Cerebral Cortex of Patients with Sporadic Parkinson’s Disease
Tafreshi, Ali , Beach, Thomas G. , Tashiro, Stephanie, Wang, Charles , Dashtipour, Khashayar , Adler, Charles H. , Chen, Xin , Serrano, Geidy E. , Tashiro, Stephanie

Mayo Clinic

Brain Sciences | June 28, 2017 | Volume: 7 | Issue: 7 | Pages: 74

10.3390/brainsci7070074 | PMID 28653979 Get It

Objective: To determine and compare DNA methylation patterns between patients with Parkinson’s disease (PD) and age- and sex-similar matched non-PD controls. Background: Epigenetic regulation is one of the major mechanisms for an organism to respond to the environment through changes in gene expression and has been implicated in numerous disease processes. We would like to examine epigenetic modification patterns that may predispose or protect against PD. Methods: Frozen tissue samples of the human cerebral cortex from 12 PD patients and 12 subjects without PD pathology were obtained. Genome-wide DNA methylation profiling was performed using the Illumina HumanMethylation450 BeadChip array. Differential methylation was defined as a mean methylation level difference (delta β) of at least 0.20 (Δβ ≥ 0.20). Methylation regions with an absolute delta β value ≥ 0.20 were selected for further gene function studies. Results: We identified 2795 differentially methylated CpG sites in the frontal cortex of PD cases with a detection p-value of ≤ 0.01 and 328 differentially methylated CpG sites with a detection p-value of ≤ 0.001. A pattern of robust hypermethylation of synphilin-1, α-synuclein-interacting protein (SNCAIP) gene was found in the brain of PD cases (p = 4.93 × 10−7 and delta β = 0.60). Conclusion: Our findings support a link between SNCAIP methylation and PD risk. Hypomethylation of SNCAIP may function to protect against PD. The current results may suggest that the methylation status of SNCAIP could be useful as a marker in PD diagnosis and treatment and warrants further investigation.
Vibrio vulnificus tonsillitis after swimming in the Gulf of Mexico
Alsaad, Ali A. , Sotello, David , Kruse, Brian, Cowart, Jennifer B. , Kruse, Brian T, Sotello Aviles, David A

Mayo Clinic

BMJ Case Reports | June 28, 2017 | Volume: 2017 | Issue: No issue available | Pages: bcr-2017-221161

10.1136/bcr-2017-221161 | PMID 28659373 Get It

Cap-dependent translational control of oncolytic measles virus infection in malignant mesothelioma
Jacobson, Blake A., Sadiq, Ahad A., Tang, Shaogeng , Jay-Dixon, Joe, Patel, Manish R. , Drees, Jeremy, Sorenson, Brent S., Russell, Stephen J. , Kratzke, Robert A. , Russell, Stephen J

Mayo Clinic

Oncotarget | June 27, 2017 | Volume: 8 | Issue: 38 | Pages: 63096-63109

10.18632/oncotarget.18656 | PMID 28968974 Get It

Depression and insomnia among individuals with celiac disease or on a gluten-free diet in the USA: results from a national survey
Zylberberg, Haley M. , Demmer, Ryan T. , Green, Peter H.R., Lebwohl, Benjamin , Murray, Joseph A. , Green, Peter H.R. , Demmer, Ryan T

Mayo Clinic

European Journal of Gastroenterology & Hepatology | June 27, 2017 | Volume: 29 | Issue: 9 | Pages: 1091-1096

10.1097/meg.0000000000000932 | PMID 28658068 Get It

Background There is uncertainty regarding the prevalence of psychiatric illnesses in patients with celiac disease (CD) and people who avoid gluten (PWAG) without a diagnosis of CD. Participants and methods We obtained data from 22 274 participants from the 2009–2014 National Health and Nutrition Examination Survey to compare the prevalence of depression, insomnia, quality-of-life variables, and psychotropic medication use in CD participants and PWAGs to controls. We used multivariable logistic regression to assess for independent associations between CD/PWAG status and the outcomes of these variables. Results Depression was present in 8.2% of controls compared with 3.9% of participants with CD (P=0.18) and 2.9% of PWAGs (P=0.002). After adjustment for age, sex, race, income, and access to healthcare, PWAGs maintained lower odds of depression compared with controls (odds ratio=0.25; 95% confidence interval: 0.12–0.51; P=0.0001). The prevalence estimates of sleep difficulty among controls (27.3%) compared to participants with CD or PWAGs were 37.7% (P=0.15) and 34.1% (P=0.11). Those with diagnosed CD had increased odds of sleep difficulty (odds ratio=2.41; 95% confidence interval 1.04–5.60), but this was no longer significant after multivariable adjustment (P=0.17). Conclusion Among a nationally representative US sample, participants with CD overall showed no increased odds of depression or sleep difficulty. PWAGs showed lower odds of depression compared with controls. Future research should investigate the relationship between a diagnosis of CD and the development of psychiatric conditions.
Cellular Senescence Biomarker p16INK4a+ Cell Burden in Thigh Adipose is Associated With Poor Physical Function in Older Women
Justice, Jamie N. , Gregory, Heather, Tchkonia, Tamar , Kirkland, James L. , Nicklas, Barbara J. , LeBrasseur, Nathan K. , Kritchevsky, Stephen B. , Tchkonia, T , Justice, Jamie N

Mayo Clinic

The Journals of Gerontology: Series A | June 27, 2017 | Volume: 73 | Issue: 7 | Pages: 939-945

10.1093/gerona/glx134 | PMID 28658942 Get It

Incidence of hematologic malignancy and cause‐specific mortality in the Women's Health Initiative randomized controlled trial of calcium and vitamin D supplementation
Ammann, Eric M. , Haraldsson, Bjarni , Wallace, Robert B. , Johnson, Karen , Lin, Emily M., Link, Brian K. , Drake, Matthew T. , Haraldsson, Bjarni , Desai, Pinkal , Link, Brian K

Mayo Clinic

Cancer | June 27, 2017 | Volume: 123 | Issue: 21 | Pages: 4168-4177

10.1002/cncr.30858 | PMID 28654155 Get It

BACKGROUNDPrior evidence of a possible link between vitamin D status and hematologic malignancy (HM) in humans comes from observational studies, leaving unresolved the question of whether a true causal relationship exists.METHODSThe authors performed a secondary analysis of data from the Women's Health Initiative Calcium/Vitamin D (CaD) trial, a large randomized controlled trial of CaD supplementation compared with placebo in older women. Kaplan‐Meier and Cox proportional hazards survival analysis methods were used to evaluate the relationship between treatment assignment and 1) incident HM and 2) HM‐specific mortality over 10 years following randomization. HMs were classified by cell type (lymphoid, myeloid, or plasma cell) and analyzed as distinct endpoints in secondary analyses.RESULTSA total of 34,763 Women's Health Initiative CaD trial participants (median age, 63 years) had complete baseline covariate data and were eligible for analysis. Women assigned to CaD supplementation had a significantly lower risk of incident HM (hazard ratio [HR], 0.80; 95% confidence interval [95% CI], 0.65‐0.99) but not HM‐specific mortality (HR, 0.77 [95% CI, 0.53‐1.11] for the entire cohort; and HR, 1.03 [95% CI, 0.70‐1.51] among incident HM cases after diagnosis). In secondary analyses, protective associations were found to be most robust for lymphoid malignancies, with HRs of 0.77 (95% CI, 0.59‐1.01) and 0.46 (95% CI, 0.24‐0.89), respectively, for cancer incidence and mortality in those assigned to CaD supplementation.CONCLUSIONSThe current post hoc analysis of data from a large and well‐executed randomized controlled trial demonstrates a protective association between modest CaD supplementation and HM risk in older women. Additional research concerning the relationship between vitamin D and HM is warranted. Cancer 2017;123:4168–4177. © 2017 American Cancer Society.
Gadolinium Deposition in Human Brain Tissues after Contrast-enhanced MR Imaging in Adult Patients without Intracranial Abnormalities
McDonald, Robert J. , Kallmes, David F. , Jentoft, Mark E. , Paolini, Michael A., Murray, David , Williamson, Eric E. , Eckel, Laurence J. , Murray, David L., McDonald, Jennifer S.

Mayo Clinic

Radiology | June 27, 2017 | Volume: 285 | Issue: 2 | Pages: 546-554

10.1148/radiol.2017161595 | PMID 28653860 Get It

Quality-of-Life (QOL) during Screening for Phase 1 Trial Studies in Patients with Advanced Solid Tumors and Its Impact on Risk for Serious Adverse Events
Anwar, Sidra , Tan, Wei, Hong, Chi-Chen, Admane, Sonal , Dozier, Askia, Siedlecki, Francine, Whitworth, Amy, DiRaddo, Ann Marie, DePaolo, Dawn, Jacob, Sandra M, Miller, Austin , Adjei, Alex A. , Dy, Grace K. , Ma, Wen Wee, Hong, Chi‐Chen , Wee, Wen , Miller, Austin

Mayo Clinic

Cancers | June 27, 2017 | Volume: 9 | Issue: 7 | Pages: 73

10.3390/cancers9070073 | PMID 28672850 Get It

Background: Serious adverse events (SAEs) and subject replacements occur frequently in phase 1 oncology clinical trials. Whether baseline quality-of-life (QOL) or social support can predict risk for SAEs or subject replacement among these patients is not known. Methods: Between 2011–2013, 92 patients undergoing screening for enrollment into one of 22 phase 1 solid tumor clinical trials at Roswell Park Cancer Institute were included in this study. QOL Questionnaires (EORTC QLQ-C30 and FACT-G), Medical Outcomes Study Social Support Survey (MOSSSS), Charlson comorbidity scores (CCS) and Royal Marsden scores (RMS) were obtained at baseline. Frequency of dose limiting toxicities (DLTs), subject replacement and SAEs that occurred within the first 4 cycles of treatment were recorded. Fisher’s exact test and Mann-Whitney-Wilcoxon test were used to study the association between categorical and continuous variables, respectively. A linear transformation was used to standardize QOL scores. p-value ≤ 0.05 was considered statistically significant. Results: Baseline QOL, MOSSSS, CCS and RMS were not associated with subject replacement nor DLTs. Baseline EORTC QLQ-C30 scores were significantly lower among patients who encountered SAEs within the first 4 cycles (p = 0.04). Conclusions: Lower (worse) EORTC QLQ-C30 score at baseline is associated with SAE occurrence during phase 1 oncology trials.
Adult disseminated Langerhans cell histiocytosis: incidence, racial disparities and long‐term outcomes
Goyal, Gaurav , Hook, C. Christopher , Wolanskyj, Alexandra P. , Call, Timothy G. , Hook, Christopher C., Shah, Meera , Rech, Karen L. , Go, Ronald S. , Goyal, Guarav , Wolanskyj-Spinner, Alexandra P

Mayo Clinic

British Journal of Haematology | June 27, 2017 | Volume: 182 | Issue: 4 | Pages: 579-581

10.1111/bjh.14818 | PMID 28653448 Get It

Clinical heterogeneity of diffuse large B cell lymphoma following failure of front‐line immunochemotherapy
Farooq, Umar , Maurer, Matthew J. , Thompson, Carrie A. , Thanarajasingam, Gita , Inwards, David J. , Micallef, Ivana N. , Macon, William R. , Syrbu, Sergei , Lin, Tasha , Lin, Yi , Ansell, Stephen M. , Nowakowski, Grzegorz S. , Link, Brian K. , Micallef, Ivana, Macon, William, Farooq, Umar , Habermann, Thomas M. , Cerhan, James R. , Maurer, Matthew , Link, Brian K , Lin, Yi , Syrbu, Sergei

Mayo Clinic

British Journal of Haematology | June 27, 2017 | Volume: 179 | Issue: 1 | Pages: 50-60

10.1111/bjh.14813 | PMID 28653407 Get It

Summary This study aimed to describe the patterns of care and outcomes of diffuse large B cell lymphoma ( DLBCL ) after failure of front line anthracycline‐based immunochemotherapy ( IC ). Patients with newly diagnosed lymphoma were prospectively enrolled in Molecular Epidemiology Resource ( MER ) of the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellzence. All DLBCL and primary mediastinal B‐cell lymphoma ( PMBL ) patients treated with front‐line anthracycline‐based IC were followed for relapse. Patients with relapse on follow‐up and subsequently retreated were included in this analysis. 1039 patients received anthracycline‐based IC between 2002 and 2012, of which 244 relapsed and were subsequently retreated. Across all therapies, overall survival at 4 years ( OS 4) from relapse was 28% and 103 patients ultimately underwent autologous haematopoietic cell transplant (auto HCT ) with OS 4 from auto HCT of 51%. Patients relapsing after 12 months from initial diagnosis had OS 4 of 47% but those with a transient or no response to initial therapy had OS 4 of only 13%. Outcomes of relapsed or refractory DLBCL differ substantially when categorized by response to initial therapy, timing of relapse and opportunity to undergo auto HCT . The design and interpretation of uncontrolled trials should account for this heterogeneity in patients with relapsed DLBCL .